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Anhedonia and substance dependence: clinical correlates and 
treatment options
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Anhedonia is a condition in which the capacity of experiencing pleasure is totally or partially lost, 
and it refers to both a state symptom in various psychiatric disorders and a personality trait. It has 
a putative neural substrate, originating in the dopaminergic mesolimbic and mesocortical reward 
circuit. Anhedonia frequently occurs in mood disorders, as a negative symptom in schizophrenia, 
and in substance use disorders. In particular, we focus our attention on the relationships 
occurring between anhedonia and substance use disorders, as highlighted by many studies. 
Several authors suggested that anhedonia is an important factor involved in relapse as well 
as in the transition from recreational use to excessive drug intake. In particular, anhedonia has 
been found to be a frequent feature in alcoholics and addicted patients during acute and chronic 
withdrawal as well as in cocaine, stimulant, and cannabis abusers. Furthermore, in subjects 
with a substance dependence disorder, there is a significant correlation between anhedonia, 
craving, intensity of withdrawal symptoms, and psychosocial and personality characteristics. 
Therefore treating anhedonia in detoxified alcohol-dependent subjects could be critical in terms 
of relapse prevention strategies, given its strong relationship with craving.
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transmitted defect both in overt schizophrenia and in compensated 
schizotypes, who do not actually experience a psychotic break-
down. According to Rado, this defect prevented the development 
of normal healthy sexual functioning, reduced enthusiasm for life, 
impaired the ability to relate with other people, and weakened the 
feelings of joy, affection, love, pride, and self-respect.
Meehl (1962, 1973) integrated theories by Rado (1956,1962) into 
a theory of neurological dysfunction in schizophrenia. He consid-
ered that low hedonic capacity, or joylessness, was a heritable trait 
predisposing to the development of schizophrenia and depression. 
For most psychiatrists it was Klein’s (1974) concept of endog-
enomorphic depression which revived interest in the concept and 
notion of anhedonia. The Diagnostic and Statistical Manual of 
Mental Disorders recognized anhedonia in its third edition, pub-
lished in 1980 (American Psychiatric Association, 1980), in which 
the concept of anhedonia was promoted to the position of one 
of the two pathognomonic features of major depressive disorder 
(MDD). Klein’s (1974) definition “a sharp, unreactive, pervasive 
impairment of the capacity to experience pleasure, or to respond 
affectively, to the anticipation of pleasure” was slightly modified 
to “a loss of interest or pleasure in all or almost all usual activities 
and pastimes” (Snaith, 1992). Furthermore, for the melancholic 
subtype of major depression, the anhedonic experience became 
essential to the definition. Actually the DSM-IV-TR defines anhe-
donia as diminished interest or pleasure in response to stimuli that 
were previously perceived as rewarding during a premorbid state 
(American Psychiatric Association, 2000).
With recent scientific advances in elucidating the genetic basis 
of psychopathology by identifying endophenotypes, anhedonia 
gradually gained renewed research attention. The importance of 
The word anhedonia was introduced in Psychiatry by Ribot (1896), 
who defined anhedonia as the inability to experience pleasure. 
Anhedonia refers to both a state symptom in various psychiatric 
disorders and a personality trait (Loas and Pierson, 1989).
A review of psychiatric textbooks in the late nineteenth century 
revealed that the loss of the pleasure response was recognized as 
an early and preeminent symptom of depression (Bucknill and 
Tuke, 1874; Clouston, 1896; Bevan, 1899). Anhedonia played an 
important role in psychopathology theories at the beginning of 
the twentieth century (Bleuler, 1911; Kraepelin, 1919; Myerson, 
1923). In particular, Kraepelin (1919) spoke of anhedonia as a core 
symptom of a state of individual suffering, which was part of the 
dementia praecox. Bleuler (1911), noting the indifference that some 
patients showed toward their friends, acquaintances, colleagues, 
and at last life itself, defined anhedonia as a basic feature of their 
disease, “an external signal of their pathological condition.”
Nevertheless  later  psychiatric  interest  in  anhedonia  faded; 
Jaspers (1913) in his “Allgemeine Psychopathologie. Ein Leitfaden 
für Studierende, Ärzte und Psychologen” does not mention anhe-
donia except as an aspect of the more severe and pervasive lost 
of all emotional response. Attention focused then on depressed 
mood as the pathognomonic feature of depressive illness. The 
International Classification of Diseases, 9th revision (ICD-9) does 
not mention anhedonia in its definition of the depressive phase of 
manic-depressive psychosis, but defines the disorder in terms of 
a “widespread depressed mood of gloom and wretchedness with 
some degree of anxiety” (World Health Organisation, 1978).
In the 1960s, interest in anhedonia rose again. Rado (1956, 1962) 
assigned anhedonia a more central role in the development of schiz-
ophrenia. He suggested that anhedonia was a central, genetically 
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  inactivation of dopamine function leads to anhedonia; this was 
suggested by cumulative evidence deriving at first from intracranial 
stimulation, then from dopaminergic antagonism of neuroleptic 
drugs, and mostly from studies on the mechanism of action of 
substances of abuse and psychostimulants (Salamone et al., 1997).
Interesting findings about altered dopamine function in anhe-
donia come from positron emission tomography (PET) and single 
photon emission computed tomography (SPECT) imaging of the 
dopamine transporter (DAT), by using the high-affinity radiotracer 
[123I]N-fluoropropyl-carbomethoxy-3β-(4-iodophenyl)tropane 
(DATSCAN).
While many studies have been conducted about dopamine dys-
function in MDD (Laasonen-Balk et al., 1999; Meyer et al., 2001; 
Amsterdam and Newberg, 2007; Yang et al., 2008), so far just a single 
study, conducted by Sarchiapone et al. (2006), focused its attention 
on individuals affected by MDD with anhedonic symptoms. This 
study was conducted on a total of 11 depressed outpatients with 
anhedonia [with a Snaith–Hamilton Pleasure Scale (SHAPS; Snaith 
et al., 1995) total score > 7 and an Hamilton Depression Rating 
Scale (HAM-D; Hamilton, 1960) score > 18] and 9 healthy com-
parison subjects, by using SPECT with the radiotracer DATSCAN 
to evaluate DAT binding. Significantly lower specific/non-specific 
DAT binding ratios were found in the putamen and caudate indi-
vidually and in the whole striatum bilaterally of depressed patients 
with anhedonia compared with control subjects.
In addition to dopamine, primarily involved in hedonic experi-
ence are endogenous opioids, like endorphins, enkephalins, dynor-
phins, and orphanin FG as well as their various receptor subtypes (μ, 
δ, κ, and ORL1; Cooper et al., 2003), which are widely expressed in 
the ventral striatum (particularly the shell of the NAcc). Stimulation 
of these receptors is believed to underlie hedonic responses to food, 
and other natural rewards (Pecina et al., 2006).
In a recent review, Treadway and Zald (2010), according to the 
theoretical models of anticipatory and consummatory pleasure 
(Klein, 1987; Berridge and Robinson, 1998; Depue and Collins, 
1999),  proposed  a  distinction  between  deficits  in  the  hedonic 
response to rewards (reward “liking”), which leads to consum-
matory anhedonia, and deficits in the motivation to pursue them 
(reward “wanting”), which leads to motivational anhedonia. Reward 
“liking” and, consequently, consummatory anhedonia would be 
linked to opioids, ventromedial prefrontal cortex, and amygdala, 
whereas reward “wanting” and motivational anhedonia would be 
linked to dopamine and basal ganglia. Furthermore, they suppose 
that it would be necessary to overcome the conceptualization of 
anhedonia as a steady-state, mood-like phenomenon; consequently, 
they proposed to introduce the term “decisional anhedonia” to 
address the influence of anhedonia on reward decision-making.
Diagnosing anheDonia
Although anhedonia is regarded as an important symptom in psy-
chopathology (Snaith, 1993; Berenbaum et al., 2003), so far it has 
received relatively little attention. This limited attention could be 
the result of the low availability of short, well-validated, and easy 
to use instruments (Franken et al., 2007).
In general, two main approaches have been utilized to investi-
gate and assess anhedonia (or hedonic capacity): laboratory-based 
measures and questionnaires.
anhedonia in psychopathology is stressed by a recent study by 
Hasler et al. (2004), who demonstrated that anhedonia, together 
with increased stress reactivity, is the most important candidate for 
psychopathological endophenotype of major depression.
Psychobiological basis of anheDonia
From  a  psychobiological  perspective,  as  proposed  by  several 
researchers, anhedonia has a putative neural substrate, the dopamin-
ergic mesolimbic and mesocortical reward circuit, which involves 
the ventral tegmental area (VTA), the ventral striatum, and part of 
the prefrontal cortex (Markou and Koob, 1991; Heinz et al., 1994; 
Isella et al., 2003; Willner et al., 2005).
The reward system is a collection of brain structures which 
attempts to regulate and control behavior by inducing pleasur-
able effects. The reward is an operational concept for describing the 
positive value that an individual ascribes to an object, behavioral 
act, or internal physical state, and its functions are based directly 
on behavior modification and indirectly on the sensory proper-
ties of rewards.
The major neurochemical pathway of the reward system in the 
brain involves the dopaminergic mesolimbic and mesocortical 
pathway. Of these pathways, the mesolimbic pathway plays the major 
role, and goes from the VTA, via the medial forebrain bundle, to the 
ventral striatum, including the nucleus accumbens (NAcc), to the 
amygdala and to the hippocampus; the mesolimbic pathway is most 
closely associated with associative learning, reward motivation and 
reinforcement. Indeed, the mesocortical pathway projects to cortical 
regions, including the anterior cingulate cortex (ACC), the orbital 
frontal cortex (OFC), the medial prefrontal cortex (mPFC), and the 
insula; this pathway is strongly associated with working memory, 
attention, and inhibitory control (Treadway and Zald, 2010).
Dopamine primarily acts on one of five post-synaptic G-protein 
coupled receptors, called D1–D5 (Cooper et al., 2003). These recep-
tors are grouped into two families, defined D1-like (including D1 
and D5 receptors) and D2-like (D2, D3, and D4 receptors). Upon 
receptor stimulation, D1-like receptor stimulation increases ade-
nylate cyclase (AC) activity, though activating protein kinase A 
(PKA) and subsequently the phosphorylation of various intracel-
lular targets, that way generating “up-states” (Surmeier et al., 2007). 
In contrast, D2-like receptor stimulation results in decreased AC 
activity, generating “downstates” (Hernandez-Lopez et al., 2000).
A central dopaminergic dysfunction has been widely proposed 
as a common neurobiological correlate of the psychopathological 
expression of anhedonia. Some studies on depressive disorders as a 
group have supported the hypothesis of a dysfunction of dopamine 
turnover as reflected by levels of homovanillic acid in cerebrospi-
nal fluid and by assessment of dopamine receptors and neuroen-
docrine function through postmortem, genetic, or neuroimaging 
techniques. Strong evidence has come from several studies on the 
effectiveness  of  dopamine  agonists  and  antagonists  in  depres-
sive illness, specifically from the recognition that pharmaceutical 
agents that enhance dopamine transmission present antidepressant 
activity (Boyer et al., 1995; Willner, 1995; Smeraldi, 1998; Brunello 
et al., 1999). The hypothesis by which rewarding events, irrespec-
tive of their modality, share the common property of activating 
the mesolimbic and the mesocortical dopamine system has been 
widely supported. Conversely, as highlighted by Wise (1982), the www.frontiersin.org  March 2011  | Volume 2  | Article 10  |  3
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symptom complex of schizophrenia; nevertheless, other studies, 
like one conducted by Myin-Germeys et al. (2001), indicate that 
schizophrenics maintain dynamics in their affect.
Although anhedonia plays a very important role in depression 
and schizophrenia, it is not just limited to them. In fact, anhedonia 
was linked to anxiety and adjustment disorders (Silverstone, 1991), 
suicidal ideation (Oei et al., 1990), and successful suicide (Fawcett, 
1993). On the other hand, in the model proposed by Loas (1996), a 
genetically determined low hedonic capacity was regarded as a spe-
cific character trait, which, together with aspects like introversion, 
obsessive-compulsivity, pessimism, and passivity, could represent 
a risk factor, which could lead, under stress conditions, to unipolar 
endogenomorphic depression.
Anhedonia is also present in other disorders and dysfunctional 
behaviors such as Parkinson’s disease (Isella et al., 2003), over-
eating (Davis and Woodside, 2002), and risky behaviors in general 
(Franken et al., 2006b).
anheDonia in substance DePenDence DisorDers
In addition to mood disorders and schizophrenia, anhedonia is also 
present in individuals with a substance use disorder.
Several authors suggested that anhedonia is part of the absti-
nence symptomatology (Gawin and Kleber, 1986) and it is an 
important factor involved in relapse (Koob and Le Moal, 2001; 
Volkow et al., 2002). Particularly interesting and worth noting is a 
study conducted by Ahmed and Koob (1998), in which it was found 
that, in an animal model, escalated cocaine use could result from 
a change in the hedonic set point for cocaine rather than from a 
simple change in sensitivity to the drug. This change, induced by 
increasing drug availability, suggests that an even longer access to 
the drug could lead to further increase in the hedonic set point. 
Therefore this work suggests that anhedonia is an important fac-
tor involved in the transition from recreational use to excessive 
drug intake.
Among substance dependences, anhedonia was found to be a 
frequent feature in alcoholics and addicted patients during acute 
and chronic withdrawal (Heinz et al., 1994), as well as in cocaine, 
stimulant, and cannabis abusers (Gawin et al., 1988; Miller et al., 
1993; Bovasso, 2001). In a study performed by Heinz et al. (1994), 
it was found that anhedonia, dysphoria, and avolition are common 
symptoms of schizophrenic, depressive, and alcohol-dependent 
patients during withdrawal. According to the authors these symp-
toms may be caused by a functional deficit of the dopaminergic 
transmission in the dopaminergic reward system. This hypothesis 
was supported by PET and SPECT findings, which showed that a 
reduced striatal density of unoccupied dopamine D2-receptors is 
correlated with extrapyramidal side-effects in neuroleptic-treated 
individuals with schizophrenia and with craving and dysphoria 
in drug-dependent patients. Similar results were found in a PET 
study conducted by Volkow et al. (1996), from which emerged that 
alcoholics show significant reductions in D2-receptors but not in 
DAT availability when compared with non-alcoholics.
As previously mentioned, anhedonia has been found to be a 
common feature in withdrawal syndrome and it is due to a cen-
tral dopaminergic dysfunction. Likewise, a hypodopaminergic 
state is also related to many substance use disorders (Melis et al., 
2005). As emerged in many studies, ethanol withdrawal decreases 
The first approach utilizes laboratory-based measures of anhedo-
nia, involving signal-detection methodology, physiologic measures, 
and subjective hedonic response to pleasant stimuli (Berenbaum 
et al., 1987; Fiorito and Simons, 1994; Ferguson and Katkin, 1996; 
Berlin et al., 1998; Pizzagalli et al., 2005). Besides these behavioral 
measures, anhedonia can also be evaluated using hemodynamic 
(Crespo-Facorro et al., 2001; Mitterschiffthaler et al., 2003; Keedwell 
et al., 2005) and electrophysiological (Simons et al., 1982; Dubal 
et al., 2000; Franken et al., 2006a) measures.
The secondary approach to the diagnosis of anhedonia involves 
the use of questionnaires. Several scales have been developed to 
assess anhedonia or hedonic capacity. Specific scales for the meas-
urement of anhedonia are the Revised Chapman Physical Anhedonia 
Scale (CPAS) and Social Anhedonia Scale (SAS; Chapman et al., 
1976; Chapman and Chapman, 1982); the Fawcett–Clark Pleasure 
Scale (FCPS; Fawcett et al., 1983); and the SHAPS (Snaith et al., 
1995). The SHAPS was built and validated on the responses of a 
large non-clinical sample from the general population, requested to 
agree or disagree with 14 different statements of hedonic response 
in pleasurable situations, which are likely to be encountered by 
most people; a cut-off value of ≥3 has been obtained to define the 
presence of anhedonia, and a rough prevalence of anhedonia in 
the general population less than 5%; the SHAPS was employed to 
assess anhedonia in different psychiatric conditions (Lampe et al., 
2001; Silver and Shlomo, 2002; Stevens et al., 2002).
Other rating instruments can be employed to evaluate anhedo-
nia within broader psychopathological dimensions, such as those 
of depression and negative symptoms of schizophrenia. The Scale 
for  the Assessment  of  Negative  Symptoms  (SANS; Andreasen, 
1989) and particularly the Subscale for Anhedonia (SANSanh) by 
Andreasen (1989) was used in patients with schizophrenia and 
with (Bersani et al., 2002) or without (Dollfus and Petit, 1995; 
Tollefson and Sanger, 1997) abuse of cannabis. The Bech–Rafaelsen 
Melancholia Scale (BRMS; Bech and Rafaelsen, 1980; Bech, 2002) 
was administered not only to melancholic patients, but also to 
acute schizophrenic subjects, in order to rate the latent dimension 
of depressive and negative symptomatology and it shows a posi-
tive correlation with SANS (Muller et al., 2002). Furthermore it is 
worth mentioning the 10-cm Visual Analogue Scale (VAS; Aitken, 
1969; Mottola, 1993) for pleasure and the Temporal Experience of 
Pleasure Scale (TEPS; Gard et al., 2006), which was developed to 
assess anticipatory and consummatory pleasure.
anheDonia in axis i DisorDers
Anhedonia has been considered crucial for the diagnosis of depres-
sion (Klein, 1974, 1987; Loas et al., 1994; Schrader, 1997), and 
schizophrenia (Andreasen, 1982; Blanchard et al., 2001; Mason 
et al., 2004; Gooding et al., 2005). It is, besides depressed mood, 
one of the two core symptoms of depression (American Psychiatric 
Association, 2000), moreover lack of reactivity and anhedonia are 
key diagnostic criteria for the DSM-IV-TR melancholic subtype 
of major depression (American Psychiatric Association, 2000). 
Anhedonia is also one of the most important negative symptoms 
frequently observed in schizophrenia (Andreasen and Olsen, 1982; 
Blanchard, 1998). For example, Blanchard and Cohen (2006) found 
evidence to suggest that anhedonia is, together with diminished 
expression, one of the two key features involved in the negative Frontiers in Psychiatry  | Addictive Disorders    March 2011  | Volume 2  | Article 10  |  4
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and GABAB receptors results in a reduced release of glutamate 
(Manzoni  and  Williams,  1999).  Therefore,  withdrawal  from 
chronic morphine modifies both inhibitory and excitatory inputs 
to VTA dopamine cells. Interestingly, while VTA dopamine neu-
rons appear to normalize within 2 weeks after acute withdrawal, 
acute morphine administration produced greater responses in rats 
with a history of morphine dependence than in controls (Diana 
et al., 1999). This finding suggests an increased sensitivity of VTA 
dopamine neurons to morphine itself, which may be relevant to 
the phenomenon of drug craving and relapse (Diana et al., 1999; 
Pulvirenti and Diana, 2001). These studies strengthen the notion 
that VTA dopamine neurons are involved in the subjective adverse 
components of withdrawal, like dysphoria, rather than in the 
somatic facets of it.
Cannabinoid withdrawal effects on VTA dopamine neuronal 
activity (Diana et al., 1998b) are reminiscent of those reported 
for ethanol and morphine. More interestingly, a reduction in VTA 
dopamine neuronal function is also observed when somatic signs 
of withdrawal are not detectable (Diana et al., 1998b). Furthermore, 
when a withdrawal is pharmacologically induced with the specific 
cannabinoid antagonist SR 141716A, the somatic signs of with-
drawal accompany the dampened VTA dopamine neuronal activity 
(Diana et al., 1998b). Similar evidence comes from a recent study by 
Spiga et al. (2010), conducted on rats withdrawn from cannabinoid, 
which demonstrates that withdrawal from addictive compounds 
alters functioning of the mesolimbic system and provides direct 
morphological evidence for functional abnormalities associated 
with cannabinoid dependence in dopaminergic neurons and their 
post-synaptic counterpart.
Similarly, nicotine withdrawal produced a decline of firing rate 
of VTA dopamine neurons that rapidly returned to control lev-
els (Rasmussen and Czachura, 1995; Liu and Jin, 2004). As it was 
found in the withdrawal from other substances of abuse (Diana 
et al., 1993, 1995a, 1998b), the number of spontaneously active 
dopamine neurons was not altered at any time after nicotine with-
drawal. Therefore, this evidence, together with other investigations 
(Diana et al., 1992, 1993, 1995b, 1998b; Bailey et al., 1998, 2001), 
suggests that the hypodopaminergic state, which accompany the 
acute phase of withdrawal, is not mediated by depolarization inac-
tivation of dopamine neurons but it reflects most likely alterations 
of intrinsic properties and extrinsic afferent regulatory mechanisms 
(Bonci and Williams, 1996, 1997; Manzoni and Williams, 1999; 
Pulvirenti and Diana, 2001; Diana and Tepper, 2002) modified by 
a chronic drug regimen and disclosed by withdrawal.
Cocaine withdrawal effects on VTA dopamine neuronal activ-
ity seem to affect the burst firing pattern (Gao et al., 1998). In 
fact, during the early withdrawal phases, it was observed a reduced 
bursting activity of VTA dopamine cells, which returned to normal 
within 7 days. In addition, alteration in the sensitivity of D2 recep-
tors seems to play an important role in cocaine-induced modifica-
tions of spontaneous activity of VTA dopamine neurons during 
the first week of withdrawal (Robertson et al., 1991; Ackerman 
and White, 1992; Gao et al., 1998; Lee et al., 1999; Marinelli et al., 
2003). Consequently, short-term treatment with D2 receptor ago-
nists restores the hypodopaminergic neuronal function (Lee et al., 
1999; Marinelli et al., 2003), thus representing a potential treatment 
for intermediate withdrawal phases.
the spontaneous activity of rat VTA dopamine neurons in vivo 
(Diana et al., 1992, 1993) and mice in vitro (Bailey et al., 1998). 
The hypoactivity of dopamine neurons correlates with a reduc-
tion of extracellular dopamine levels in the NAcc (Rossetti et al., 
1992; Diana et al., 1993; Fadda and Rossetti, 1998) and might 
represent the neural basis of the dysphoric state observed after the 
abrupt interruption of chronic ethanol intake. Interestingly, this 
hypodopaminergic state outlasts the physical signs of withdrawal 
(Diana et al., 1996; Bailey et al., 2001) and can be terminated 
by administration of ethanol itself (Diana et al., 1993, 1996). 
Particularly, a study by Diana et al. (1993), conducted in rats with-
drawn from chronic ethanol administration, showed that spon-
taneous firing rates, spikes per burst, and absolute burst firing, 
but not the number of spontaneously active VTA dopaminergic 
neurons, were found drastically reduced. Furthermore, dopamine 
outflow in the NAcc was reduced after abruptly stopping chronic 
ethanol administration. All these changes, as well as ethanol with-
drawal behavioral signs, were reversed by ethanol administra-
tion. This reversal suggested that the abrupt cessation of chronic 
ethanol administration plays a causal role in the reduction of 
mesolimbic dopaminergic activity seen in the ethanol withdrawal 
syndrome. Thus these results indicate that during the ethanol 
withdrawal syndrome the mesolimbic dopaminergic system activ-
ity is tonically reduced. Considering the role of the mesolimbic 
dopaminergic system in the reinforcing properties of ethanol, the 
depressed activity of this system during the ethanol withdrawal 
syndrome may be relevant to the dysphoric state associated with 
ethanol withdrawal in humans.
Along with typical withdrawal symptoms, anhedonia and crav-
ing may arise independently during the phase of abstinence from 
rewarding psychoactive substances, but their intensity, temporal 
pattern, and responsivity to treatment do not appear to overlap. In 
the so-called protracted withdrawal, the syndrome that is usually 
described as depression could be better interpreted as anhedonia, 
and it cannot be merely attributed to the psychological effects of 
abstinence (Jaffe et al., 1997). Diana et al. (1996) took into evidence 
that anhedonia is associated with craving and dysphoric mood 
in an animal model of alcohol dependence with abrupt ethanol 
discontinuation. This study indicates that physiological symptoms 
of ethanol withdrawal syndrome (i.e., tremors, motor impairment, 
and reduced seizure threshold) and the decline in dopaminergic 
neuronal activity responsible for anhedonia, show a different time 
course, with the hypoactivity of the dopaminergic system emerging 
later and lasting longer.
Similar results were found for morphine (Diana et al., 1995a, 
1999; Bonci and Williams, 1997), cannabinoids (Diana et al., 
1998a,b;  Spiga  et  al.,  2010),  and  nicotine  (Rasmussen  and 
Czachura, 1995; Epping-Jordan et al., 1998; Harrison et al., 2001). 
Particularly, morphine withdrawal causes a deep decline of fir-
ing rate and bursting activity of VTA dopamine neurons (Diana 
et al., 1995a,b), which persists long after the behavioral signs of 
withdrawal have ceased (Diana et al., 1999). During acute with-
drawal from chronic morphine administration, an upregulation 
of the cAMP-dependent cascade produces a long-lasting increased 
probability of GABA release in the VTA (Bonci and Williams, 1996, 
1997). Moreover, an increased sensitivity to presynaptic inhibi-
tion by both group II metabotropic glutamate receptors (mGluRs) www.frontiersin.org  March 2011  | Volume 2  | Article 10  |  5
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community could be effective on anhedonia, while the interactive 
and substance-oriented approach of the self-help groups could be 
effective for craving. In conclusion, what emerges from this study 
is that there are significant interrelations between hedonic capa-
bility, craving, and protracted withdrawal, although the strongest 
association proved to be between hedonic capability and craving; 
in particular craving is positively associated with anhedonia levels 
and negatively with hedonic capability. In the data by Janiri et al. 
(2005) this model appears to properly fit in the opiates-dependent 
group, probably because in opiate dependence craving is particu-
larly intense due to the concurrence of reward and relief craving.
The data by Janiri et al. (2005) were confirmed and enriched 
by  following  studies  made  by  Martinotti  et  al.  (2008a),  who 
found that the positive correlation between the Clinical Institute 
Withdrawal Assessment for Alcohol (CIWA-Ar; Sullivan et al., 1989) 
score and anhedonia scales was in line with the hypothesis that 
the clinical dimension of anhedonia cannot be separated from 
the other behavioral symptoms of withdrawal and should thus be 
considered as part of the same process. This study was conducted 
on 102 detoxified subjects meeting the clinical criteria for Alcohol 
Dependence in Remission, who were subdivided into four groups 
according to the length of abstinence. Withdrawal symptoma-
tology was assessed through the CIWA-Ar; whereas the level of 
craving for alcohol was evaluated through a 10-cm VAS (Aitken, 
1969; Mottola, 1993), and anhedonia was investigated through 
the SHAPS (Snaith et al., 1995) and the Subscale for Anhedonia 
of the Scale for the Assessment of Negative Symptoms (SANSanh; 
Andreasen, 1989). Furthermore, a 10-cm VAS for pleasure was 
given  to  directly  assess  the  hedonic  capability.  According  to 
Martinotti et al. (2008a) the strong correlation of some specific 
withdrawal symptoms like “nausea” and “headache, fullness in 
head” with anhedonia scales leads to assume that they may rep-
resent physical correlates of anhedonia. It is worth noting that 
the findings describing alcohol addicts as a population in which 
somatoform disorders are possible (Bott et al., 2005), and the 
study by Simon et al. (1999), describing gastrointestinal discom-
fort and headache as two of the most common pain complaints 
in depressive disorders, are in line with this hypothesis. Moreover, 
the correlation between anhedonia scales and “orientation and 
clouding of sensorium” in the groups of subjects abstinent for a 
period between 90 to 180 and 180 to 365 days, and the increase 
of this parameter between the four considered groups, lead to 
consider this symptom as a possible derivate of both protracted 
withdrawal and the subclinical neuropsychological deterioration, 
which outlast the detoxification up to 1 year. In fact, patients in 
this phase of their abstinence may perceive their performances 
as lower than those expected on the basis of their long-lasting 
alcohol-free condition; therefore it may represent a component of 
anhedonia itself, more than a physiologic correlate of protracted 
withdrawal. On the other hand, craving did not positively cor-
relate with withdrawal symptoms, thus providing evidence that 
the physical aspects of withdrawal may present a different time 
course with respect to craving, as previously highlighted by data 
from Diana et al. (1996) and Heinz et al. (2004). Therefore the 
results of the study by Martinotti et al. (2008a) suggest that the 
clinical dimension of anhedonia cannot be separated from the 
other behavioral symptoms of withdrawal and should thus be 
During amphetamine withdrawal the spontaneous activity of 
VTA dopamine neurons does not seem to be altered (Lee et al., 
1989);  however  repeated  exposure  to  amphetamine  produces 
long-lasting changes in the modulation of glutamatergic synaptic 
transmission by amphetamine in the NAcc (Li and Kauer, 2004).
Further evidence of this hypodopaminergic state, which under-
lies both withdrawal syndrome and anhedonia, comes from more 
recent imaging studies, as those by Martinez et al. (2005,2009) and 
Volkow et al. (1996, 1997, 2002), that were previously discussed. 
Martinez et al. (2005) found that a decrease in D2 receptors and 
mesolimbic dopamine transmission predisposes animals to con-
sume alcohol. This study measured D2 receptors and dopamine 
transmission in human alcohol-dependent subjects using PET and 
[11C]raclopride; subjects were scanned before and after a psychos-
timulant challenge (amphetamine 0.3 mg/kg intravenous). In par-
ticular, [11C]raclopride binding potential was significantly reduced 
by 16.6% in the limbic striatum, 19.2% in the associative striatum, 
and 21.3% in the sensorimotor striatum in alcohol-dependent 
subjects compared with healthy control. What emerged from this 
study is that alcohol dependence was associated with a decrease in 
D2 receptors in each striatal subdivision, whereas amphetamine-
induced dopamine release was reduced in the limbic striatum only. 
Similar results were found by Martinez et al. (2009), in cocaine-
dependent subjects.
Interesting  findings  about  the  presence  and  correlation  of 
anhedonia in substance-related disorders were found by Janiri 
et al. (2005) about anhedonia and substance-related symptoms in 
detoxified substance-dependent subjects. In this study 70 patients 
were enrolled; they came from three different therapeutic settings: 
a Therapeutic Community, the Day-Hospital of Psychiatry and 
Drug Dependence of the University General Hospital “A. Gemelli” 
in Rome, and Self-Help Groups. Furthermore, patients were subdi-
vided into three groups according to the used, or mainly used, drug: 
dependent on opiates, dependent on alcohol, and dependent on at 
least two abused substances (multiple substance   disorder – MSD). 
Each patient was abstinent at the time of the study. Anhedonia 
was investigated through three different measurement scales: the 
SHAPS (Snaith et al., 1995), the SANS (Andreasen, 1989), and 
the BRMS (Bech and Rafaelsen, 1980; Bech, 2002). The only cut-
off score utilized for a clinical judgment was the SHAPS score 
≥3, indicating the presence of anhedonia. Moreover, a 10-cm 
VAS (Aitken, 1969; Mottola, 1993) for pleasure was also given to 
directly assess the hedonic capability, while the level of craving 
for the specific abused substance was evaluated through a 10-cm 
VAS for craving. According to the substance previously used, no 
significant interaction effect between the three groups was seen 
with regard to all the anhedonia scales and VAS for craving, and 
with regard to anhedonia and craving. However more subtle dif-
ferences between the groups considered could have been hardly 
determined because of the paucity of the samples. With regard to 
the comparison between the groups divided according to the site of 
recruitment a difference emerged: in the Therapeutic Community 
group less anhedonic subjects were found than in others, while a 
significantly lower level of craving was detected in the self-help 
groups. Since social support and socializing activities are liable to 
prevent anhedonia and craving (Gilbert et al., 2002), it is conceiv-
able that the supportive and protective setting of the therapeutic Frontiers in Psychiatry  | Addictive Disorders    March 2011  | Volume 2  | Article 10  |  6
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the treatment of anheDonia
What emerged from the previously cited studies is that, in sub-
jects with a substance use disorder, there is a correlation between 
anhedonia, craving (Janiri et al., 2005), intensity of withdrawal 
symptoms (Martinotti et al., 2008a), and psychosocial and per-
sonality characteristics (Martinotti et al., 2008b; Pozzi et al., 2008). 
Furthermore, anhedonia and dysphoric mood are associated with 
the hypoactivity of the dopaminergic system (Guyon et al., 1993; 
Jaffe et al., 1997; Volkow et al., 1997; Martin-Soelch et al., 2001; 
Schmidt et al., 2001; Melis et al., 2005).
On this premise many different therapeutic strategies have been 
developed to treat anhedonia; in general two main approaches have 
been utilized: psychotherapy and pharmacological treatment.
Among psychotherapeutic techniques, behavioral activation 
(BA) might be particularly appropriate in cases with motiva-
tional anhedonia. BA was initially developed as a component of 
cognitive behavioral therapy (CBT), from which it differs prima-
rily in its conceptualization of patient cognitions as a rumina-
tive behavior (Dimidjian et al., 2006). The goal of BA is to help 
patients to identify whether they are engaging in rewarding or 
non-rewarding behaviors, and to make behavioral choices that 
are likely to increase exposure to positively reinforcing experi-
ences. As suggested by initial evidence coming from studies by 
Coffman et al. (2007), BA may surpass CBT by emphasizing 
an increase in motivated behaviors, particularly with patients 
diagnosed with comorbid personality disorders. Recent evidence 
of the efficacy of BA and CBT in anhedonia comes from func-
tional magnetic resonance imaging (fMRI) studies, which have 
shown that treatment response to CBT results in a progressive 
decrease in amygdala sensitivity to negative stimuli (Siegle et al., 
2006), while successful treatment with BA leads to increased 
BOLD responses of the striatum during reward anticipation 
(Dichter et al., 2009).
Among pharmacological treatments the main target is rep-
resented by the dopaminergic reward system, which results to 
be  hypoactive  in  patients  experiencing  anhedonia.  Therefore 
dopamine-active  pharmacotherapies  are  recommended.  These 
include psychostimulants, dopamine agonists, and the norepine-
phrine/dopamine  reuptake  inhibitor  bupropion.  In  particular, 
bupropion is the most widely used in clinical practice. However, 
the pharmacological profile of bupropion is complex, and its effects 
on reward processing in animals and humans may rely on a variety 
of mechanisms, some of which are still not completely known.
Bupropion has little direct effect on serotonin function (Stahl 
et al., 2004). Several studies exploring bupropion occupancy of 
DAT at clinical doses have reported occupancy rates ranging from 
14 to 26% in the striatum (Meyer et al., 2002; Kugaya et al., 2003; 
Learned-Coughlin et al., 2003); moreover bupropion increases 
the activity of the intracellular vesicular monoamine transporter 
2 (VMAT2) protein, which may enhance extracellular dopamine 
by increasing available dopamine in presynaptic pools (Rau et al., 
2005). Bupropion may also exert specific influence over dopamine 
function through its action as an inhibitor of the norepinephrine 
transporter (NET), which is the primary transporter of dopamine 
in prefrontal regions. More recent work suggested that bupropion 
decreases the activity of nicotinic acetylcholine receptors (nAChRs; 
Dwoskin et al., 2006).
considered as part of the same process; furthermore it highlights 
the relevance of protracted withdrawal well beyond the limited 
period following the abrupt cessation of alcohol intake.
In another study, Martinotti et al. (2008b) investigated the rela-
tionships between anhedonia, craving, and temperament and char-
acter dimensions in a sample of patients with alcohol and opiate 
dependence, recruited after a period of detoxification. The authors 
found that the temperament dimension of novelty seeking (NS; 
Cloninger et al., 1993) was positively correlated to both craving 
and anhedonia, with a higher score of NS in the subsample of 
anhedonic subjects with respect to both non-anhedonic and control 
subjects. In this study, the possibility that difficulty in experiencing 
pleasure in psychiatric disorders can lead to the use of psychoac-
tive substances in an attempt to decrease anhedonia, is extended 
to subjects without psychiatric disorders, who may try substances 
to counterbalance a tonic state of anhedonia.
The influence of recent clinical and social-environmental factors 
on hedonic capability and related psychopathology were investi-
gated in a study by Pozzi et al. (2008). This study was conducted 
on a sample of 70 patients manifesting dependence on alcohol, 
opiates, or multiple drugs, without severe comorbidity. The meas-
urement scales for anhedonia SHAPS (Snaith et al., 1995), SANS 
(Andreasen, 1989), and BRMS (Bech and Rafaelsen, 1980; Bech, 
2002) were administered together with the European adaptation 
of the Addiction Severity Index (EuropASI; Blanken et al., 1994; 
Koeter and Hartgers, 1997). The composite scores from the seven 
areas of the EuropASI were introduced as independent factors in a 
stepwise regression analysis having symptom scores of anhedonia 
as dependent variables. What emerged from this work is that the 
EuropASI composites do not explain the variability of the scores 
of anhedonia. Only in few cases the regression models showed a 
weak predictive capacity for medical status, alcohol use, and drug 
use composite scores, with R-square values ranging from 10 to 22%. 
In conclusion, this cross-sectional study showed that anhedonia is 
a psychopathological entity independent from other clinical and 
psychosocial features of detoxified addicts without severe comorbid 
psychopathology.
From a psychobiological perspective a relationship has been 
found between anhedonia, craving, and dysphoric mood with the 
hypoactivity of the dopaminergic system, particularly in dopamine 
outflow in the NAcc of rats withdrawn from chronic alcohol 
administration (Schmidt et al., 2001). Therefore these data con-
firm the relationship between the hypoactivity of the dopaminergic 
system and anhedonia in substance use disorders, as supported 
by previous studies based on animal models (Guyon et al., 1993; 
Jaffe et al., 1997; Willner, 1997). Nevertheless, in clinical studies 
a dopamine central receptor dysfunction was shown to occur as 
a correlate of affective blunting rather than anhedonia (Schmidt 
et al., 2001).
Imaging studies provided evidence of disrupted sensitivity to 
natural reinforces in the reward circuits of drug addicted subjects, 
which could represent a putative mechanism underlying dys-
phoria and anhedonia experienced during withdrawal (Martin-
Soelch et al., 2001; Volkow et al., 2002). The same decreased 
striatal dopaminergic responsiveness was found by Volkow et al. 
(1997) in detoxified cocaine-dependent subjects with craving 
and a reduced “high” experienced in specific pleasant situations.www.frontiersin.org  March 2011  | Volume 2  | Article 10  |  7
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reduction of anhedonia in patients receiving ALC at 1 and 3 g/day 
was found. In conclusion, the results of this study indicate the effi-
cacy and safety of ALC in the treatment of anhedonia, melancholia, 
and negative symptoms in anhedonic alcoholics after 10 days of 
intravenous therapy. Accordingly, ALC may be considered as a new 
potentially useful drug for the treatment of anhedonia.
Recent evidences suggest the efficacy of some second-generation 
antipsychotics on the treatment of anhedonia in a population of 
alcohol-dependent subject; in particular, recent works highlight 
the role of aripiprazole (Kenna et al., 2004a,b; Janiri et al., 2007; 
Martinotti et al., 2007, 2009) and quetiapine (Orsetti et al., 2007, 
2009; Martinotti et al., 2008c).
Aripiprazole, rather than antagonizing the D2 receptor, acts as a D2 
partial agonist (Lawler et al., 1999; Burstein et al., 2005), as a partial 
agonist at the 5-HT1A receptor, and like the other atypical antipsychot-
ics displays an antagonist profile at the 5-HT2A receptor (Jordan et al., 
2002; Shapiro et al., 2003). It also antagonizes the 5-HT7 receptor and 
acts as a partial agonist at the 5-HT2C receptor, both with high affin-
ity. Aripiprazole has moderate affinity for histamine, α-adrenergic, 
and D4 receptors as well as the serotonin transporter, while it has no 
appreciable affinity for cholinergic muscarinic acetylcholine receptors 
(mAChRs; Shapiro et al., 2003). Recently, it has been demonstrated 
that in 5-HT7 receptor knockout mice, aripiprazole does not reduce 
immobility time in the FST, and actually increases it (Hedlund, 2009; 
Sarkisyan et al., 2010). This implicates 5-HT7 antagonism as playing 
a major role in the antidepressant effects of aripiprazole, similarly to 
amisulpride (Abbas et al., 2009; Hedlund, 2009; Sarkisyan et al., 2010).
Martinotti et al. (2009) performed a randomized, double-blind, 
confrontation trial with naltrexone, which aim was to investigate 
the efficacy of aripiprazole on alcohol-drinking indices, craving, 
and psychiatric symptom, such as anhedonia. This study was con-
ducted on 75 alcohol-dependent subjects and demonstrated that 
patients treated with aripiprazole remained abstinent from any 
alcohol amount for a longer time with respect to those treated with 
naltrexone; furthermore aripiprazole was efficacious in attenuat-
ing psychopathological symptom severity, including anhedonia; 
however, as for craving scores, patients treated with naltrexone 
showed a better outcome.
Quetiapine is a dibenzothiazepine derivative that has a greater 
affinity for serotonin 5-HT2 receptors than dopamine D2 receptors, 
together with a considerable activity at histamine H1 receptors, 
α1- and α2-adrenergic receptors. Even though quetiapine itself is 
not able to activate these receptors, it behaves as a competitive 
antagonist, and therefore prevents the effects of endogenous neu-
rotransmitters at these sites. In addition, quetiapine has partial 
agonist activity at serotonin 5-HT1A receptors, while it has clinically 
negligible anticholinergic properties.
Martinotti et al. (2008c) investigated the safety and efficacy of 
quetiapine in the treatment of alcohol dependence comorbid with 
disorders characterized by high levels of mood and behavioral insta-
bility. This study was conducted on 28 alcohol-dependent subjects 
and demonstrated that quetiapine decreased alcohol consumption, 
craving for alcohol, and psychiatric symptoms intensity, including 
anhedonia, maintaining a good level of tolerance. 
Interesting findings about the effects of quetiapine treatment on 
anhedonia came also from animal study performed by Orsetti et al. 
(2007, 2009). In a study published in 2007 (Orsetti et al., 2007) they 
Bupropion may represent a valid treatment for anhedonia, as 
suggested by animal studies; rats treated with bupropion dem-
onstrated decreased immobility time during the forced swim test 
(FST) and tail suspension tests (Cryan et al., 2001, 2004), and 
showed greater willingness to work for food rewards during a pro-
gressive ratio task (Bruijnzeel and Markou, 2003). Further evidence 
over the effectiveness of bupropion in the treatment of symptoms 
related to anhedonia, comes from studies by Bodkin et al. (1997) 
and Tomarken et al. (2004).
On the purpose to treat anhedonia, melancholic, and negative 
symptoms in anhedonic alcoholics, Martinotti et al. (2010) pro-
posed the use of acetyl-l-carnitine (ALC). ALC is an endogenous 
compound representing a small amount of the physiological pool 
of carnitines (Juliet et al., 2003). The main physiological role of 
ALC is to contribute to the homeostasis of coenzyme A, export-
ing acetyl-CoA groups from the mitochondria (Bremer, 1983). 
Pharmacologically, it acts as a precursor of acetylcholine (White 
and Scates, 1990) and stimulates intermediate energy production 
(Aureli et al., 1990) and cytochrome oxidase activity in mitochon-
dria (Villa and Gorini, 1991). Furthermore ALC modulate, either 
directly or indirectly through activation of cholinergic receptors, 
the N-methyl-d-aspartate (NMDA) subtype of glutamate receptors 
(Calvani and Carta, 1992). ALC may facilitate cholinergic neu-
rotransmission either directly or by shuttling acetyl groups that 
can be used for acetylcholine (Gibson and Shimada, 1980; Janiri 
and Tempesta, 1983; Burlina et al., 1989; White and Scates, 1990). 
ALC has an excitatory activity on cortical cholinergic neurons 
(Nakamura et al., 1998) and moderate synthesis of acetylcholine 
from ALC has been observed (Falchetto et al., 1971). Janiri et al. 
(1991) showed that ALC exerted a mild excitatory effect on corti-
cal cholinergic receptors in vivo, providing further evidence of the 
influence of ALC on the cholinergic system.
With regard to the effect of ALC on dopamine outflow, mostly 
implicated in alcohol and substance use disorders, carnitine sup-
plementation has been shown to significantly increase the levels 
of dopamine in the cortex, hippocampus, and striatum of rat 
brain (Juliet et al., 2003), while animal studies have shown that 
ALC administration persistently increases dopamine outflow in 
the NAcc (Scheggi et al., 2004). In addition, the acute administra-
tion of ALC increases β-endorphin and cortisol plasma levels in 
healthy subjects, and normalizes them in patients with demen-
tia, Alzheimer’s disease and depression. The mechanism of action 
of ALC in depression may involve effects on the cell membrane, 
GABA neurotransmission, and serotonergic modulation (Tempesta 
et al., 1985).
A recent study by Martinotti et al. (2011) evaluated the efficacy 
of ALC, at different dosages, on specific anhedonic symptoms in 
detoxified alcohol-dependent subjects. Secondary endpoints were 
the effect of ALC on melancholic and negative symptoms. The study 
was conducted on 64 alcohol-dependent anhedonic patients, who 
were subdivided into three groups: 23 received ALC at a dosage of 
3 g/day, 21 received ALC at a dosage of 1 g/day, and 20 were given 
placebo. The presence of anhedonic symptoms was determined by 
the SHAPS (Snaith et al., 1995) and the Visual Analogue Scale for 
Anhedonia (VASa; Aitken, 1969; Mottola, 1993); negative, and mel-
ancholic symptoms were evaluated by the SANS (Andreasen, 1989) 
and the BRMS (Bech and Rafaelsen, 1980; Bech, 2002). A significant Frontiers in Psychiatry  | Addictive Disorders    March 2011  | Volume 2  | Article 10  |  8
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In conclusion, we believe that the importance of anhedonia as a 
symptom is fundamental and should be thus properly highlighted. 
As previously noted, anhedonia has relevant implication in the 
pathogenesis of several psychiatric disorders, of which it represents 
one of the major symptoms; moreover, it has revealed to have pos-
sible treatment implications. In point of fact treating anhedonia, 
of which the neuropsychobiology has been deeply investigated, 
could mean treating the underlying pathology. In particular, within 
substance-dependent disorder, treating anhedonia in detoxified 
dependent subjects, could be critical in terms of relapse preven-
tion strategies, given its strong relationship with craving, since the 
higher the craving scores the higher the level of anhedonia. In the 
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found that the administration of quetiapine at a dosage of 2 mg/
kg/day, prevents the onset of anhedonia in rats exposed to a 6-week 
chronic mild stress (CMS) protocol. The effect of quetiapine has 
a slow onset, beginning at week 5, and causes a complete recovery 
from anhedonia. In this respect, the effect of quetiapine is similar 
to that obtained after chronic administration of amitriptyline 2 
or 5 mg/kg/day. Findings from Orsetti et al. (2007) also indicate 
that a 6-week administration of quetiapine, 2 or 10 mg/kg/day, 
has protective effects against the onset of anhedonia caused by 
the exposure to an acute subthreshold stressful event in rats that 
have previously experienced the CMS procedure. Thus, this results 
suggest that quetiapine is able to prevent both the transient mood 
depression caused by acute stress and the long-lasting anhedonic 
state induced by exposure, over a period of weeks, to a variety of 
unpredictable mild stressors.
In a more recent study, Orsetti et al. (2009) investigated the 
molecular mechanisms of quetiapine antidepressant effect by 
coupling the CMS protocol with Affymetrix microarray tech-
nology to screen the entire rat genome for gene changes in the 
frontal cortex. This work showed that the action of quetiap-
ine prevents the stress induced impairment of some processes 
either involved in central nervous system development or having 
a crucial role for viability of neural cells and cell to cell commu-
nications, like signal transduction regulation, inorganic cation 
transport, membrane organization, and neurite morphogenesis. 
Therefore, Orsetti et al. (2009) showed that chronic quetiapine 
treatment prevented anhedonia and reversed, at least in part, the 
changes of gene expression induced by CMS in the rat frontal 
cortex. They also identified that 11 genes (Ptgs2, Gad1, Plcb1, 
Camk2a, Homer1, Senp2, Junb, Nfib, Hes5, Capon, and Marcks), 
representing molecular targets of quetiapine, are presumably the 
effectors of its clinical efficacy.
conclusion
As originally formulated by Ribot (1896), anhedonia consists of 
the inability to experience pleasure, and it refers to both a state 
symptom in various psychiatric disorders and a personality trait. 
Anhedonia can be found in many psychiatric disorders, such as 
major depression and mood disorders in general, schizophrenia, 
as well as in Parkinson’s disease, over-eating, and risky behaviors.www.frontiersin.org  March 2011  | Volume 2  | Article 10  |  9
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